Physician profile
Christopher Bergin
NPI 1730915141
$1,672.73
in general payments reported to CMS, 2019-2025
16 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $152 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.39 |
| Education | $285.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $291.01 | 2025 | Nemluvio |
| Genzyme Corporation | $222.91 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $175.13 | 2025 | Dupixent |
| Abbvie INC. | $172.09 | 2025 | |
| Sun Pharmaceutical Industries INC. | $151.39 | 2025 | |
| Pfizer INC. | $125.00 | 2024 | |
| Botanix Sb INC | $104.55 | 2025 | Sofdra |
| Janssen Biotech, INC. | $94.99 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $92.00 | 2025 | |
| Incyte Corporation | $67.54 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $44.50 | 2025 | |
| Arcutis Biotherapeutics, INC. | $41.53 | 2025 | Zoryve |
| Leo Pharma INC. | $33.76 | 2025 | Adbry |
| Lilly USA, LLC | $21.74 | 2025 | Ebglyss |
| Cipher Pharmaceuticals US LLC | $18.34 | 2025 | Natroba, Spinosad |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $16.25 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.